Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
- DOI
- 10.1007/s41669-023-00432-z
- Published
- 2024 Jan
- Container
- PharmacoEconomics - open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s41669-023-00432-z,
title = {Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.},
author = {Fauchier L and Lamblin N and Tardu J and Bellier L and Groyer H and Ittah D and Chollet J and Linden S and Levy P},
year = {2024},
journal = {PharmacoEconomics - open},
doi = {10.1007/s41669-023-00432-z},
url = {https://doi.org/10.1007/s41669-023-00432-z}
}RIS
TY - JOUR TI - Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial. AU - Fauchier L AU - Lamblin N AU - Tardu J AU - Bellier L AU - Groyer H AU - Ittah D AU - Chollet J AU - Linden S AU - Levy P PY - 2024 JO - PharmacoEconomics - open DO - 10.1007/s41669-023-00432-z UR - https://doi.org/10.1007/s41669-023-00432-z ER -
APA
L, F., N, L., J, T., L, B., H, G., D, I., J, C., S, L., & P, L. (2024). Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE(®)) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.. PharmacoEconomics - open. https://doi.org/10.1007/s41669-023-00432-z
Source records
- pubmed · retrieved 2026-09-26T06:04:55.028Z